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OTHER SOURCES OF INFORMATION 
HBV and HCV 
For additional information about hepatitis B and hepatitis C, call the hepatitis 
information line at 1-888-4-HEPCDC (1-888–443-7232) or visit CDC’s hepatitis 
website at www.cdc.gov/hepatitis. 
Any reaction or adverse health event after getting hepatitis B vaccine sould be 
reported to your healthcare provider.  The Vaccine Adverse Event Reporting 
System (1-800-822-7967) receives reports from healthcare providers and others 
about vaccine side effects. 
HIV 
Information specialists who staff the CDC National AIDS Hotline (1-800-
342-2437) can answer questions or provide information on HIV infection and 
AIDS and the resources available in your area.  The HIV/AIDS Treatment 
Information Service (1-800-448-0440) can also be contacted for information on 
the clinical treatment of HIV/AIDS. For free copies of printed material on 
HIV infection and AIDS, please call or write the CDC National Prevention 
Information Network, P.O. Box 6003, Rockville, MD 20849-6003, telephone 
1-800-458-5231, Internet address www.cdcnpin.org.  Additional information 
about occupational exposures to bloodborne pathogens is available on CDC’s 
Division of Healthcare Quality Promotion’s website at www.cdc.gov/ncidod/hip 
or by calling 1-800-893-0485 and on CDC’s National Institute of Occupational 
Safety and Health’s website at www.cdc.gov/niosh or call 1-800-35 NIOSH 
(1-800-356-4674). 
HBV-HCV-HIV 
PEPline (the National Clinicians’ Postexposure Prophylaxis Hotline) is a 24-
hour, 7-day-a-week consultation service for clinicians managing occupational 
exposures.  This service is supported by the Health Resources and Services 
Administration Ryan White CARE Act and the AIDS Education and Training 
Centers and CDC. PEPline can be contacted by phone at (888) 448-4911 (toll 
free) or on the Internet at http://pepline.ucsf.edu/pepline. 
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Exposure to Blood 
What Healthcare Personnel Need to Know 
OCCUPATIONAL EXPOSURES TO BLOOD 
Introduction 
Healthcare personnel are at risk for occupational exposure to bloodborne patho-
gens, including hepatitis B virus (HBV), hepatitis C virus (HCV), and human 
immunodeficiency virus (HIV).  Exposures occur through needlesticks or cuts 
from other sharp instruments contaminated with an infected patient's blood or 
through contact of the eye, nose, mouth, or skin with a patient's blood. Important 
factors that influence the overall risk for occupational exposures to bloodborne 
pathogens include the number of infected individuals in the patient population 
and the type and number of blood contacts. Most exposures do not result in 
infection. Following a specific exposure, the risk of infection may vary with 
factors such as these: 
 The pathogen involved 
 The type of exposure 
 The amount of blood involved in the exposure 
 The amount of virus in the patient's blood at the time of exposure 
Your employer should have in place a system for reporting exposures in order to 
quickly evaluate the risk of infection, inform you about treatments available to 
help prevent infection, monitor you for side effects of treatments, and determine 
if infection occurs. This may involve testing your blood and that of the source 
patient and offering appropriate postexposure treatment. 
How can occupational exposures be prevented? 
Many needlesticks and other cuts can be prevented by using safer techniques 
(for example, not recapping needles by hand), disposing of used needles in 
appropriate sharps disposal containers, and using medical devices with safety 
features designed to prevent injuries.  Using appropriate barriers such as gloves, 
eye and face protection, or gowns when contact with blood is expected can 
prevent many exposures to the eyes, nose, mouth, or skin. 
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IF AN EXPOSURE OCCURS 
What should I do if I am exposed to the  blood of a patient? 
1. Immediately following an exposure to blood: 
 Wash needlesticks and cuts with soap and water 
 Flush splashes to the nose, mouth, or skin with water 
 Irrigate eyes with clean water, saline, or sterile irrigants 
No scientific evidence shows that using antiseptics or squeezing the wound will 
reduce the risk of transmission of a bloodborne pathogen. Using a caustic agent 
such as bleach is not recommended. 
2. Report the exposure to the department (e.g., occupational health, infec-
tion control) responsible for managing exposures.  Prompt reporting is essential 
because, in some cases, postexposure treatment may be recommended and it 
should be started as soon as possible. Discuss the possible risks of acquiring 
HBV, HCV, and HIV and the need for postexposure treatment with the provider 
managing your exposure.  You should have already received hepatitis B vaccine, 
which is extremely safe and effective in preventing HBV infection. 
RISK OF INFECTION AFTER EXPOSURE 
What is the risk of infection after an occupational exposure? 
HBV 
Healthcare personnel who have received hepatitis B vaccine and developed 
immunity to the virus are at virtually no risk for infection. For a susceptible 
person, the risk from a single needlestick or cut exposure to HBV-infected blood 
ranges from 6-30% and depends on the hepatitis B e antigen (HBeAg) status of 
the source individual.  Hepatitis B surface antigen (HBsAg)-positive individu-
als who are HBeAg positive have more virus in their blood and are more likely 
to transmit HBV than those who are HBeAg negative.  While there is a risk for 
HBV infection from exposures of mucous membranes or nonintact skin, there is 
no known risk for HBV infection from exposure to intact skin. 
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HCV 
The average risk for infection after a needlestick or cut exposure to HCV-

infected blood is approximately 1.8%. The risk following a blood exposure 

to the eye, nose or mouth is unknown, but is believed to be very small; 

however, HCV infection from blood splash to the eye has been reported.  

There also has been a report of HCV transmission that may have resulted 

from exposure to nonintact skin, but no known risk from exposure to intact skin.
 
HIV 
	 The average risk of HIV infection after a needlestick or cut 
exposure to HlV-infected blood is 0.3% (i.e., three-tenths of one 
percent, or about 1 in 300). Stated another way, 99.7% of 
needlestick/cut exposures do not lead to infection. 
	 The risk after exposure of the eye, nose, or mouth to HIV-infected 
blood is estimated to be, on average, 0.1% (1 in 1,000). 
	 The risk after exposure of non-intact skin to HlV-infected blood is 
estimated to be less than 0.1%. A small amount of blood on intact skin 
probably poses no risk at all. There have been no documented cases of 
HIV transmission due to an exposure involving a small amount of blood 
on intact skin (a few drops of blood on skin for a short period of time). 
How many healthcare personnel have been infected with blood-
borne pathogens? 
HBV 
The annual number of occupational infections has decreased 95% since hepatitis 
B vaccine became available in 1982, from >10,000 in 1983 to <400 in 2001 
(CDC, unpublished data). 
HCV 
There are no exact estimates on the number of healthcare personnel occupation-
ally infected with HCV.  However, studies have shown that 1% of hospital 
healthcare personnel have evidence of HCV infection (about 3% of the U.S. 
population has evidence of infection).  The number of these workers who may 
have been infected through an occupational exposure is unknown. 
HIV 
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As of December 2001, CDC had received reports of 57 documented cases and 
138 possible cases of occupationally acquired HIV infection among healthcare 
personnel in the United States since reporting began in 1985. 
TREATMENT FOR THE EXPOSURE 
Is vaccine or treatment available to prevent infections with blood-
borne pathogens? 
HBV 
As mentioned above, hepatitis B vaccine has been available since 1982 to pre-
vent HBV infection.  All healthcare personnel who have a reasonable chance of 
exposure to blood or body fluids should receive hepatitis B vaccine.  Vaccination 
ideally should occur during the healthcare worker’s training period.  Workers 
should be tested 1-2 months after the vaccine series is complete to make sure 
that vaccination has provided immunity to HBV infection.  Hepatitis B immune 
globulin (HBIG) alone or in combination with vaccine (if not previously vacci-
nated) is effective in preventing HBV infection after an exposure.  The decision 
to begin treatment is based on several factors, such as: 
 Whether the source individual is positive for hepatitis B surface 
antigen 
 Whether you have been vaccinated 
 Whether the vaccine provided you immunity 
HCV 
There is no vaccine against hepatitis C and no treatment after an exposure that 
will prevent infection.  Neither immune globulin nor antiviral therapy is recom-
mended after exposure.  For these reasons, following  recommended infection 
control practices to prevent percutaneous injuries is imperative. 
HIV 
There is no vaccine against HIV.  However, results from a small number of stud-
ies suggest that the use of some antiretroviral drugs after certain occupational 
exposures may reduce the chance of HIV transmission.  Postexposure prophy-
laxis (PEP) is recommended for certain occupational exposures that pose a risk 
of transmission. However, for those exposures without risk of HIV infection, 
PEP is not recommended because the drugs used to prevent infection may have 
serious side effects.  You should discuss the risks and side effects with your 
healthcare provider before starting PEP for HIV. 
How are exposures to blood from an individual whose infection 
4 
  
  
 
 
status is unknown handled? 
HBV–HCV–HIV 
If the source individual cannot be identified or tested, decisions regarding 
follow-up should be based on the exposure risk and whether the source is 
likely to be infected with a bloodborne pathogen.  Follow-up testing should be 
available to all personnel who are concerned about possible infection through 
occupational exposure. 
What specific drugs are recommended for postexposure treatment? 
HBV 
If you have not been vaccinated, then hepatitis B vaccination is recommended 
for any exposure regardless of the source person’s HBV status.  HBIG and/or 
hepatitis B vaccine may be recommended depending on the source person’s 
infection status, your vaccination status and, if vaccinated, your response to the 
vaccine. 
HCV 
There is no postexposure treatment that will prevent HCV infection. 
HIV 
The Public Health Service recommends a 4-week course of a combination of 
either two antiretroviral drugs for most HIV exposures, or three antiretroviral 
drugs for exposures that may pose a greater risk for transmitting HIV (such as 
those involving a larger volume of blood with a larger amount of HIV or a 
concern about drug-resistant HIV). Differences in side effects associated with 
the use of these drugs may influence which drugs are selected in a specific 
situation. These recommendations are intended to provide guidance to clinicians 
and may be modified on a case-by-case basis.  Determining which drugs and 
how many drugs to use or when to change a treatment regimen is largely a matter 
of judgment. Whenever possible, consulting an expert with experience in the use 
of antiviral drugs is advised, especially if a recommended drug is not available, 
if the source patient's virus is likely to be resistant to one or more recommended 
drugs, or if the drugs are poorly tolerated. 
How soon after exposure to a bloodborne pathogen should 
treatment start? 
HBV 
Postexposure treatment should begin as soon as possible after exposure, prefer-
ably within 24 hours, and no later than 7 days. 
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HIV 
Treatment should be started as soon as possible, preferably within hours as 
opposed to days, after the exposure.  Although animal studies suggest that 
treatment is less effective when started more than 24-36 hours after exposure, the 
time frame after which no benefit is gained in humans is not known.  Starting 
treatment after a longer period (e.g., 1 week) may be considered for exposures 
that represent an increased risk of transmission. 
Has the FDA approved these drugs to prevent bloodborne virus 
infection following an occupational exposure? 
HBV 
Yes.  Both hepatitis B vaccine and HBIG are approved for this use. 
HIV 
No. The FDA has approved these drugs only for the treatment of existing HIV 
infection, but not as a treatment to prevent infection.  However, physicians may 
prescribe any approved drug when, in their professional judgment, the use of 
the drug is warranted. 
What is known about the safety and side effects of these drugs? 
HBV 
Hepatitis B vaccine and HBIG are very safe.  There is no information that the 
vaccine causes any chronic illnesses.  Most illnesses reported after a hepatitis 
B vaccination are related to other causes and not the vaccine.  However, you 
should report to your healthcare provider any unusual reaction after a hepatitis 
B vaccination. 
HIV 
All of the antiviral drugs for treatment of HIV have been associated with 
side effects.  The most common side effects include upset stomach (nausea, 
vomiting, diarrhea), tiredness, or headache.  The few serious side effects that 
have been reported in healthcare personnel using combinations of antiviral drugs 
after exposure have included kidney stones, hepatitis, and suppressed blood 
cell production. Protease inhibitors (e.g., indinavir and nelfinavir) may interact 
with other medicines and cause serious side effects and should not be taken in 
combination with certain other drugs, such as non-sedating antihistamines, e.g., 
Claritin®. If you need to take antiviral drugs for an HIV exposure, it is important 
to tell the healthcare provider managing your exposure about any medications 
you are currently taking. 
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 Can pregnant healthcare personnel take the drugs recommended 
for postexposure treatment? 
HBV 
Yes.  Women who are pregnant or breast-feeding can receive the hepatitis B 
vaccine and/or HBIG.  Pregnant women who are exposed to blood should be 
vaccinated against HBV infection, because infection during pregnancy can cause 
severe illness in the mother and a chronic infection in the newborn.  The vaccine 
does not harm the fetus. 
HIV 
Pregnancy should not rule out the use of postexposure treatment when it is 
warranted.  If you are pregnant you should understand what is known and not 
known regarding the potential benefits and risks associated with the use of anti-
viral drugs in order to make an informed decision about treatment. 
FOLLOW-UP AFTER AN EXPOSURE 
What follow-up should be done after an exposure? 
HBV 
Because postexposure treatment is highly effective in preventing HBV infection, 
CDC does not recommend routine follow-up after treatment.  However, any 
symptoms suggesting hepatitis (e.g., yellow eyes or skin, loss of appetite, 
nausea, vomiting, fever, stomach or joint pain, extreme tiredness) should be 
reported to your healthcare provider.  If you receive hepatitis B vaccine, you 
should be tested 1-2 months after completing the vaccine series to determine if 
you have responded to the vaccine and are protected against HBV infection. 
HCV 
You should be tested for HCV antibody and liver enzyme levels (alanine amino-
transferase or ALT) as soon as possible after the exposure (baseline) and at 4-6 
months after the exposure.  To check for infection earlier, you can be tested for 
the virus (HCV RNA) 4-6 weeks after the exposure.  Report any symptoms sug-
gesting hepatitis (mentioned above) to your healthcare provider. 
7 
  
 
HIV 
You should be tested for HIV antibody as soon as possible after exposure (base-
line) and periodically for at least 6 months after the exposure (e.g., at 6 weeks, 
12 weeks, and 6 months). If you take antiviral drugs for postexposure treatment, 
you should be checked for drug toxicity by having a complete blood count and 
kidney and liver function tests just before starting treatment and 2 weeks after 
starting treatment. You should report any sudden or severe flu-like illness that 
occurs during the follow-up period, especially if it involves fever, rash, muscle 
aches, tiredness, malaise, or swollen glands.  Any of these may suggest HIV 
infection, drug reaction, or other medical conditions. You should contact the 
healthcare provider managing your exposure if you have any questions or prob-
lems during the follow-up period. 
What precautions should be taken during the follow-up period? 
HBV 
If you are exposed to HBV and receive postexposure treatment, it is unlikely 
that you will become infected and pass the infection on to others. No precautions 
are recommended. 
HCV 
Because the risk of becoming infected and passing the infection on to others 
after an exposure to HCV is low, no precautions are recommended. 
HIV 
During the follow-up period, especially the first 6-12 weeks when most infected 
persons are expected to show signs of infection, you should follow recommen-
dations for preventing transmission of HIV.  These include not donating blood, 
semen, or organs and not having sexual intercourse.  If you choose to have 
sexual intercourse, using a condom consistently and correctly may reduce the 
risk of HIV transmission. In addition, women should consider not breast-feed-
ing infants during the follow-up period to prevent the possibility of exposing 
their infants to HIV that may be in breast milk. 
PREVENTION OF OCCUPATIONAL INFECTIONS WITH HBV, HCV,
OR HIV 
Hepatitis B virus is largely preventable through vaccination.  For HBV, HCV, 
and HIV, however, preventing occupational exposures to blood can prevent 
occupational infections with HBV, HCV, and HIV.  This includes using appro-
priate barriers such as gown, gloves and eye protection as appropriate, safely 
handling needles and other sharp instruments, and using devices with safety 
features. 
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